Key Points
- CEO Eric Lefkofsky sold 250,000 Tempus AI shares for approximately $19.4 million at an average price of $77.47, reducing his direct ownership by 71.43% to 100,000 shares. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan.
- Tempus AI’s latest quarter exceeded expectations, with adjusted EPS of negative $0.04 versus consensus of negative $0.14 and revenue of $382.5 million, up 21.6% year over year. Analysts nevertheless maintain a consensus “Hold” rating with an average price target of $69.63.
- The stock was trading at $82.24, up 7.4%, while institutional investors owned 24.22% of the company. A separate $529,650 sale by the chief accounting officer added to recent insider-selling activity.
Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) CEO Eric Lefkofsky sold 250,000 shares of the company's stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price of $77.47, for a total value of $19,367,500.00. Following the completion of the sale, the chief executive officer directly owned 100,000 shares of the company's stock, valued at approximately $7,747,000. This trade represents a 71.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Tempus AI Trading Up 7.4%
NASDAQ:TEM opened at $82.24 on Friday. The company has a market capitalization of $14.84 billion, a PE ratio of -57.11 and a beta of 3.72. Tempus AI, Inc. has a 52-week low of $40.77 and a 52-week high of $104.32. The stock's 50 day moving average price is $58.96 and its 200 day moving average price is $53.65. The company has a quick ratio of 3.16, a current ratio of 3.30 and a debt-to-equity ratio of 3.06.
Tempus AI (NASDAQ:TEM - Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.14) by $0.10. The company had revenue of $382.49 million during the quarter, compared to analysts' expectations of $379.69 million. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The firm's revenue for the quarter was up 21.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.22) earnings per share. On average, research analysts anticipate that Tempus AI, Inc. will post -1.38 EPS for the current year.
Tempus AI News Roundup
Here are the key news stories impacting Tempus AI this week:
- Positive Sentiment: Tempus AI was included among AI-powered medical stocks recommended for consideration in the fourth quarter. The article points to AI adoption in precision medicine and drug development as long-term growth drivers for Tempus. Buy 3 AI-Powered Medical Stocks to Strengthen Your Portfolio in Q4
- Positive Sentiment: Tempus AI also appeared in a list of artificial-intelligence stocks for investors to research, providing additional exposure to the company’s AI growth narrative. Top Artificial Intelligence Stocks To Research - September 23rd
- Neutral Sentiment: A market-data report stated that short interest was 0 shares as of September 24, with a 0.0-day days-to-cover ratio. If accurate, this suggests little evidence of short-covering demand, although the figure may reflect a data-reporting issue. Tempus AI short-interest data
- Negative Sentiment: CEO Eric Lefkofsky sold 250,000 shares for approximately $19.4 million, reducing his direct stake by 71.43%. The transaction occurred under a pre-arranged Rule 10b5-1 plan, which reduces its significance as a discretionary bearish signal but still adds insider-selling pressure. Tempus AI CEO Form 4 filing
- Negative Sentiment: Tempus AI’s chief accounting officer separately sold $529,650 of stock, adding to recent insider-selling concerns. Tempus AI Chief Accounting Officer Sells $529,650 of Stock
Analyst Ratings Changes
A number of brokerages recently weighed in on TEM. Needham & Company LLC reiterated a "buy" rating and set a $75.00 price target on shares of Tempus AI in a research note on Friday, July 31st. Stifel Nicolaus reduced their target price on shares of Tempus AI from $60.00 to $50.00 and set a "hold" rating for the company in a report on Monday, August 3rd. BTIG Research increased their target price on shares of Tempus AI from $70.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 20th. Cantor Fitzgerald began coverage on Tempus AI in a report on Wednesday, September 2nd. They set an "overweight" rating and a $80.00 price target on the stock. Finally, Raymond James Financial set a $80.00 price target on Tempus AI in a research report on Wednesday, September 2nd. Eleven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $69.63.
Check Out Our Latest Research Report on Tempus AI
Hedge Funds Weigh In On Tempus AI
A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Eagle Health Investments LP acquired a new position in Tempus AI during the first quarter worth $11,588,000. Alethea Capital Management LLC purchased a new stake in shares of Tempus AI during the 4th quarter worth $1,863,000. Aristotle Atlantic Partners LLC purchased a new stake in shares of Tempus AI during the 1st quarter worth $6,179,000. Headlands Technologies LLC acquired a new position in shares of Tempus AI during the 2nd quarter worth $2,689,000. Finally, Lingotto Investment Management LLP grew its stake in shares of Tempus AI by 45.9% during the 4th quarter. Lingotto Investment Management LLP now owns 1,143,526 shares of the company's stock worth $67,525,000 after purchasing an additional 359,667 shares during the period. 24.22% of the stock is currently owned by hedge funds and other institutional investors.
About Tempus AI
(
Get Free Report)
Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.
Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.
The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
